Gene Therapy On Neurological Diseases Global Market Report 2025

Description

Gene therapy for neurological diseases involves using genetic material to treat or prevent disorders affecting the brain, spinal cord, and nervous system. This approach delivers corrective genes into a patient's cells through viral or non-viral vectors to address the underlying genetic causes of neurological conditions. It aims to restore normal gene function, slow disease progression, or alleviate symptoms by targeting the root genetic causes rather than merely managing symptoms.

The primary types of gene therapy for neurological diseases include viral gene therapy and non-viral gene therapy. Viral gene therapy utilizes engineered viruses as delivery vectors to transport therapeutic genes into a patient's cells to treat or prevent diseases. These therapies target a range of neurological disorders, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), Huntington's disease, and multiple sclerosis. They can be administered via various routes such as intravenous, intrathecal, intranasal, intracerebral, and others, and are applied across different settings, including hospitals and clinics.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The gene therapy on neurological diseases market research report is one of a series of new reports from The Business Research Company that provides gene therapy on neurological diseases market statistics, including the gene therapy on neurological diseases industry global market size, regional shares, competitors with the gene therapy on neurological diseases market share, detailed gene therapy on neurological diseases market segments, market trends, and opportunities, and any further data you may need to thrive in the gene therapy on neurological diseases industry. This gene therapy on neurological diseases market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The gene therapy on neurological diseases market size has grown rapidly in recent years. It will grow from $3.13 billion in 2024 to $3.55 billion in 2025 at a compound annual growth rate (CAGR) of 13.2%. The growth during the historic period can be attributed to the increasing prevalence of neurological disorders, rising demand for personalized medicine, growing investments in biotechnology research and development, expanding clinical trial activities, and a rising number of approvals for gene therapies.

The gene therapy on neurological diseases market size is expected to see rapid growth in the next few years. It will grow to $5.76 billion in 2029 at a compound annual growth rate (CAGR) of 12.9%. The growth during the forecast period can be attributed to rising global clinical trial activity, expanding healthcare infrastructure, increasing awareness of rare diseases, a growing pipeline of gene therapies, and a surge in partnerships and collaborations. Key trends in the forecast period include the integration of technology in remote patient monitoring, innovations in vector manufacturing platforms, automation driven by advanced technologies in biomanufacturing, development of gene therapies for ultra-rare pediatric central nervous system (CNS) disorders, and the incorporation of genomic screening in clinical settings.

The increasing prevalence of neurological disorders is expected to drive growth in the gene therapy for neurological diseases market in the coming years. Neurological disorders affect the brain, spinal cord, and nerves, leading to cognitive, motor, and sensory impairments. Their prevalence is rising largely due to the aging population, as aging diminishes neuronal function, reduces brain plasticity, and increases oxidative stress, all of which contribute to the onset and progression of these conditions. Gene therapy offers a transformative approach by targeting the underlying genetic causes of neurological diseases, providing potential long-term or permanent treatment solutions. By restoring or modifying gene function, it helps reduce symptoms, improve outcomes, and minimize the need for repetitive treatments, thereby enhancing quality of life. For example, in July 2024, the National Health Service in the UK reported 487,432 patients diagnosed with dementia by June 30, 2024, an increase of 3,155 cases compared to May 31, 2024. This growing disease burden is fueling the expansion of the gene therapy for neurological diseases market.

Leading companies in this market are developing advanced viral delivery systems, such as adeno-associated virus serotype 2 (AAV2) vectors, to improve targeted gene delivery, enhance treatment efficacy, reduce immune responses, and enable durable therapeutic effects. AAV2 vectors are non-pathogenic viral carriers engineered to deliver therapeutic genes into neurons for long-term expression. For instance, in November 2024, PTC Therapeutics Inc., a US-based biopharmaceutical company, received FDA approval for a gene therapy treating aromatic L-amino acid decarboxylase (AADC) deficiency. This therapy uses an AAV2 vector to deliver a functional DDC gene into the putamen, restoring dopamine production and improving motor function. Administered as a one-time intraputaminal infusion, it provides sustained benefits, significantly improving mobility and reducing severe symptoms without the need for repeated interventions.

In November 2022, Kriya Therapeutics Inc., a US-based biopharmaceutical company, acquired Redpin Therapeutics Inc. for an undisclosed amount. This acquisition expanded Kriya's neurology-focused gene therapy pipeline, adding Redpin's chemogenetics platform and lead programs targeting epilepsy and trigeminal neuralgia. Redpin Therapeutics is a US-based biotechnology company developing innovative gene therapies for neurological diseases.

Major players in the gene therapy on neurological diseases market are Novartis AG, Biogen Inc., Neurocrine Biosciences Inc., Sarepta Therapeutics Inc., PTC Therapeutics Inc., Amicus Therapeutics Inc., Oxford Biomedica plc, Regenxbio Inc., Passage Bio Inc., Intellia Therapeutics Inc., Voyager Therapeutics Inc., UniQure N.V., AviadoBio Ltd., Capsida Biotherapeutics Inc., StrideBio Inc., Lysogene S.A., Wave Life Sciences Ltd., Taysha Gene Therapies Inc., Abeona Therapeutics Inc., CRISPR Therapeutics AG.

North America was the largest region in the gene therapy on neurological diseases market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gene therapy on neurological diseases market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the gene therapy on neurological diseases market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gene therapy on neurological diseases market consists of revenues earned by entities by providing services such as gene delivery and vector development, clinical trial services, personalised therapy development, regulatory consulting and compliance, and manufacturing support. The market value includes the value of related goods sold by the service provider or included within the service offering. The gene therapy on neurological diseases market also includes sales of gene therapy vectors, plasmid deoxyribonucleic acid (DNA), ribonucleic acid (RNA)-based therapeutics, cell lines and reagents, and neurologically targeted gene therapies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Gene Therapy On Neurological Diseases Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on gene therapy on neurological diseases market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for gene therapy on neurological diseases ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The gene therapy on neurological diseases market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: Viral Gene Therapy; Non-Viral Gene Therapy
2) By Target Disease: Alzheimer's Disease; Parkinsons Disease; Amyotrophic Lateral Sclerosis (ALS); Huntington's Disease; Multiple Sclerosis
3) By Administration Route: Intravenous; Intrathecal; Intranasal; Intracerebral; Other Administration Routes
4) By Application: Hospital; Clinic; Other Applications
Subsegments:
1) By Viral Gene Therapy Type: Adeno Associated Virus; Lentivirus; Retrovirus; Herpes Simplex Virus; Adenovirus
2) By Non-Viral Gene Therapy Type: Liposomes; Nanoparticles; Electroporation; Gene Gun; Naked Plasmid Deoxyribonucleic Acid (DNA)
Companies Mentioned: Novartis AG; Biogen Inc.; Neurocrine Biosciences Inc.; Sarepta Therapeutics Inc.; PTC Therapeutics Inc.; Amicus Therapeutics Inc.; Oxford Biomedica plc; Regenxbio Inc.; Passage Bio Inc.; Intellia Therapeutics Inc.; Voyager Therapeutics Inc.; UniQure N.V.; AviadoBio Ltd.; Capsida Biotherapeutics Inc.; StrideBio Inc.; Lysogene S.A.; Wave Life Sciences Ltd.; Taysha Gene Therapies Inc.; Abeona Therapeutics Inc.; CRISPR Therapeutics AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r37765

1. Executive Summary

2. Gene Therapy On Neurological Diseases Market Characteristics

3. Gene Therapy On Neurological Diseases Market Trends And Strategies

4. Gene Therapy On Neurological Diseases Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Gene Therapy On Neurological Diseases Growth Analysis And Strategic Analysis Framework

5.1. Global Gene Therapy On Neurological Diseases PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Gene Therapy On Neurological Diseases Market Growth Rate Analysis
5.4. Global Gene Therapy On Neurological Diseases Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Gene Therapy On Neurological Diseases Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Gene Therapy On Neurological Diseases Total Addressable Market (TAM)

6. Gene Therapy On Neurological Diseases Market Segmentation

6.1. Global Gene Therapy On Neurological Diseases Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Viral Gene Therapy
Non-Viral Gene Therapy
6.2. Global Gene Therapy On Neurological Diseases Market, Segmentation By Target Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Alzheimers Disease
Parkinsons Disease
Amyotrophic Lateral Sclerosis (ALS)
Huntingtons Disease
Multiple Sclerosis
6.3. Global Gene Therapy On Neurological Diseases Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Intravenous
Intrathecal
Intranasal
Intracerebral
Other Administration Routes
6.4. Global Gene Therapy On Neurological Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital
Clinic
Other Applications
6.5. Global Gene Therapy On Neurological Diseases Market, Sub-Segmentation Of Viral Gene Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Adeno Associated Virus
Lentivirus
Retrovirus
Herpes Simplex Virus
Adenovirus
6.6. Global Gene Therapy On Neurological Diseases Market, Sub-Segmentation Of Non-Viral Gene Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Liposomes
Nanoparticles
Electroporation
Gene Gun
Naked Plasmid DNA

7. Gene Therapy On Neurological Diseases Market Regional And Country Analysis

7.1. Global Gene Therapy On Neurological Diseases Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Gene Therapy On Neurological Diseases Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Gene Therapy On Neurological Diseases Market

8.1. Asia-Pacific Gene Therapy On Neurological Diseases Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Gene Therapy On Neurological Diseases Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Gene Therapy On Neurological Diseases Market, Segmentation By Target Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Gene Therapy On Neurological Diseases Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Gene Therapy On Neurological Diseases Market

9.1. China Gene Therapy On Neurological Diseases Market Overview
9.2. China Gene Therapy On Neurological Diseases Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Gene Therapy On Neurological Diseases Market, Segmentation By Target Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Gene Therapy On Neurological Diseases Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Gene Therapy On Neurological Diseases Market

10.1. India Gene Therapy On Neurological Diseases Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Gene Therapy On Neurological Diseases Market, Segmentation By Target Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Gene Therapy On Neurological Diseases Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Gene Therapy On Neurological Diseases Market

11.1. Japan Gene Therapy On Neurological Diseases Market Overview
11.2. Japan Gene Therapy On Neurological Diseases Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Gene Therapy On Neurological Diseases Market, Segmentation By Target Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Gene Therapy On Neurological Diseases Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Gene Therapy On Neurological Diseases Market

12.1. Australia Gene Therapy On Neurological Diseases Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Gene Therapy On Neurological Diseases Market, Segmentation By Target Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Gene Therapy On Neurological Diseases Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Gene Therapy On Neurological Diseases Market

13.1. Indonesia Gene Therapy On Neurological Diseases Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Gene Therapy On Neurological Diseases Market, Segmentation By Target Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Gene Therapy On Neurological Diseases Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Gene Therapy On Neurological Diseases Market

14.1. South Korea Gene Therapy On Neurological Diseases Market Overview
14.2. South Korea Gene Therapy On Neurological Diseases Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Gene Therapy On Neurological Diseases Market, Segmentation By Target Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Gene Therapy On Neurological Diseases Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Gene Therapy On Neurological Diseases Market

15.1. Western Europe Gene Therapy On Neurological Diseases Market Overview
15.2. Western Europe Gene Therapy On Neurological Diseases Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Gene Therapy On Neurological Diseases Market, Segmentation By Target Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Gene Therapy On Neurological Diseases Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Gene Therapy On Neurological Diseases Market

16.1. UK Gene Therapy On Neurological Diseases Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Gene Therapy On Neurological Diseases Market, Segmentation By Target Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Gene Therapy On Neurological Diseases Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Gene Therapy On Neurological Diseases Market

17.1. Germany Gene Therapy On Neurological Diseases Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Gene Therapy On Neurological Diseases Market, Segmentation By Target Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Gene Therapy On Neurological Diseases Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Gene Therapy On Neurological Diseases Market

18.1. France Gene Therapy On Neurological Diseases Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Gene Therapy On Neurological Diseases Market, Segmentation By Target Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Gene Therapy On Neurological Diseases Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Gene Therapy On Neurological Diseases Market

19.1. Italy Gene Therapy On Neurological Diseases Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Gene Therapy On Neurological Diseases Market, Segmentation By Target Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Gene Therapy On Neurological Diseases Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Gene Therapy On Neurological Diseases Market

20.1. Spain Gene Therapy On Neurological Diseases Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Gene Therapy On Neurological Diseases Market, Segmentation By Target Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Gene Therapy On Neurological Diseases Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Gene Therapy On Neurological Diseases Market

21.1. Eastern Europe Gene Therapy On Neurological Diseases Market Overview
21.2. Eastern Europe Gene Therapy On Neurological Diseases Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Gene Therapy On Neurological Diseases Market, Segmentation By Target Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Gene Therapy On Neurological Diseases Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Gene Therapy On Neurological Diseases Market

22.1. Russia Gene Therapy On Neurological Diseases Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Gene Therapy On Neurological Diseases Market, Segmentation By Target Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Gene Therapy On Neurological Diseases Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Gene Therapy On Neurological Diseases Market

23.1. North America Gene Therapy On Neurological Diseases Market Overview
23.2. North America Gene Therapy On Neurological Diseases Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Gene Therapy On Neurological Diseases Market, Segmentation By Target Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Gene Therapy On Neurological Diseases Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Gene Therapy On Neurological Diseases Market

24.1. USA Gene Therapy On Neurological Diseases Market Overview
24.2. USA Gene Therapy On Neurological Diseases Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Gene Therapy On Neurological Diseases Market, Segmentation By Target Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Gene Therapy On Neurological Diseases Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Gene Therapy On Neurological Diseases Market

25.1. Canada Gene Therapy On Neurological Diseases Market Overview
25.2. Canada Gene Therapy On Neurological Diseases Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Gene Therapy On Neurological Diseases Market, Segmentation By Target Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Gene Therapy On Neurological Diseases Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Gene Therapy On Neurological Diseases Market

26.1. South America Gene Therapy On Neurological Diseases Market Overview
26.2. South America Gene Therapy On Neurological Diseases Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Gene Therapy On Neurological Diseases Market, Segmentation By Target Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Gene Therapy On Neurological Diseases Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Gene Therapy On Neurological Diseases Market

27.1. Brazil Gene Therapy On Neurological Diseases Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Gene Therapy On Neurological Diseases Market, Segmentation By Target Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Gene Therapy On Neurological Diseases Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Gene Therapy On Neurological Diseases Market

28.1. Middle East Gene Therapy On Neurological Diseases Market Overview
28.2. Middle East Gene Therapy On Neurological Diseases Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Gene Therapy On Neurological Diseases Market, Segmentation By Target Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Gene Therapy On Neurological Diseases Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Gene Therapy On Neurological Diseases Market

29.1. Africa Gene Therapy On Neurological Diseases Market Overview
29.2. Africa Gene Therapy On Neurological Diseases Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Gene Therapy On Neurological Diseases Market, Segmentation By Target Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Gene Therapy On Neurological Diseases Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Gene Therapy On Neurological Diseases Market Competitive Landscape And Company Profiles

30.1. Gene Therapy On Neurological Diseases Market Competitive Landscape
30.2. Gene Therapy On Neurological Diseases Market Company Profiles
- 30.2.1. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Neurocrine Biosciences Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Sarepta Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. PTC Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Gene Therapy On Neurological Diseases Market Other Major And Innovative Companies

31.1. Amicus Therapeutics Inc.
31.2. Oxford Biomedica plc
31.3. Regenxbio Inc.
31.4. Passage Bio Inc.
31.5. Intellia Therapeutics Inc.
31.6. Voyager Therapeutics Inc.
31.7. UniQure N.V.
31.8. AviadoBio Ltd.
31.9. Capsida Biotherapeutics Inc.
31.10. StrideBio Inc.
31.11. Lysogene S.A.
31.12. Wave Life Sciences Ltd.
31.13. Taysha Gene Therapies Inc.
31.14. Abeona Therapeutics Inc.
31.15. CRISPR Therapeutics AG

32. Global Gene Therapy On Neurological Diseases Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Gene Therapy On Neurological Diseases Market

34. Recent Developments In The Gene Therapy On Neurological Diseases Market

35. Gene Therapy On Neurological Diseases Market High Potential Countries, Segments and Strategies

35.1 Gene Therapy On Neurological Diseases Market In 2029 - Countries Offering Most New Opportunities
35.2 Gene Therapy On Neurological Diseases Market In 2029 - Segments Offering Most New Opportunities
35.3 Gene Therapy On Neurological Diseases Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer